Friday February 16, 9:08 am Eastern Time
Entering clinical trials for the first time this year will be a proprietary small molecule in development for the treatment of multiple sclerosis, a chronic, often disabling autoimmune disorder affecting 350,000 patients in the United States. This novel, patentable compound has been shown in pre-clinical studies to prevent the onset of disease or slow its progression in several mouse models of multiple sclerosis. The compound, which would be administered orally, appears to hold inappropriately activated immune system cells in check, which may prevent the tissue damage associated with multiple sclerosis. The compound was discovered using Genzyme's novel cell-based high throughput screening approach.